Support for Africa’s vaccine production is good for the world
The strength of a strong and reliable vaccine in Africa is good for the global population, which deserves global support.
The start of the new year is often a time to reflect and reevaluate. As the epidemic expands into its third year, concerns about the health crisis and related economic uncertainties are proving difficult to resolve.
So, for anyone hoping to restore a sense of optimism, I have a simple recommendation:
Think of Africa
In early December, I toured the region મારી my first time since the Covid-19 outbreak-and I had the opportunity to visit Senegal and the Democratic Republic of the Congo. I have seen first hand the creativity, energy and spirit of entrepreneurship that the region is enduring to face this crisis.
My visit to the Institute Pasteur in Dakar, in particular, was one of these inspirations. The organization is already a world-class leader in the fight against infectious diseases, attracting and training international and regional experts. Now, the staff there is leading the way in tackling Africa’s immediate Covid-19 challenge. They are also building the region’s capacity to fight future epidemics and meet Africa’s more regular vaccination needs.
It is important that the region has the resources and the necessary funding to increase the production and production capacity of vaccines. This need is especially acute because the overall covid vaccination rate on the continent is still below 10 percent. As Africa faces a fourth wave of infections, the emergence of the Omicron variant is further a reminder that the region’s ability to equip itself to fight this epidemic and address future healthcare needs has global implications.
Meeting today’s needs
Despite the impressive efforts of the Institute Pasteur, for now, Africa is dependent on the import and donation of the COVID-19 vaccine. Guaranteeing vaccine delivery should be the most immediate priority by Covex and the African Vaccine Acquisition Trust (AVAT). Funding will also be needed for Africa’s health systems to quickly vaccinate the local population as new supplies arrive, including through outreach efforts to replicate the importance of vaccines and reduce misinformation and vaccine shrinkage. In addition to vaccines, the region needs access to tests, treatment and protective equipment.
Last year, IMF staff proposed Plan to end the epidemicBy the end of 2021, 40 percent of the population of all countries and by mid-2022, 70 percent ** by vaccination. Progress has been impressive, but the world should do better. The distribution of vaccines and other equipment continues at two alarmingly different speeds. In Africa, for example, only seven countries reached the 40 percent target in 2021, and for many, the 70 percent goal seems increasingly ambitious.
All this will require further cooperation and support from the international community. For example, closing the V 23 billion financing gap in access to the COVID-19 Tools (ACT) accelerator would be the first welcome step, as much of this effort is directed to Africa. And progress toward vaccine equity is not just a matter of addressing vaccine supply; Countries also need more support to strengthen the ‘Last Mile’ delivery.
Frankly, this is not an international support charity. This is global public good! We all know that no one is safe unless everyone is safe.
Building resilience for the future
But we must not allow future needs to be met at the expense of future needs. Boosting Resilience Against the Covid-19 or any other disease that may arise in the future, including the ability of the region to supply itself – is also a priority for the future. Without a predictable and reliable supply of vaccines, for example, health officials are often forced to respond to short instructions to accept doses, often with limited shelf life, complicating delivery logistics for already stretched health systems. In short, true resilience in Africa cannot depend on the repeated generosity of the international community. It needs scale-up Local Production capacity and strong regional supply chain.
Africa Africa Vaccination is needed – and it is achievable.
Vaccine production is a state-of-the-art enterprise that requires specialized equipment, inputs, storage facilities and skilled labor. But anyone who tells you that this cannot be done in Africa does not care.
The work of the Institute Pasteur in Dakar reflects the region’s ambitions in global efforts against the disease. With financial support from the United States, the European Union, and international foundations સમજ with prudent use of some of Senegal’s recent SDR allocations નવી construction of a new manufacturing facility is already underway. When completed, it will be one of the first start-to-finish factories on the continent, and will likely be a critical component in Africa’s supply of COVID-19 and other vaccines.
And the organization is far from the only center of excellence in the region તે part of an influential Africa-wide health and science community that is making invaluable contributions to global health જેમાં including, more recently, the discovery and sequencing of the Omicron variant. Currently, there are 12 manufacturing facilities in six African countries – Algeria, Egypt, Morocco, Rwanda, Senegal and South Africa – either operational or in the pipeline – which is expected to produce a wide range of COVID-19 vaccines.
Global public good
As we think of the new year, it is becoming increasingly clear that the ability to have a strong and reliable vaccine in Africa is a global public interest that deserves global support. For the current crisis or for the future epidemic, we all have a stake in the success of Africa.
I have no doubt that Africa is at work. But the international community can help advance cross-border collaboration in science – and must; Promote technological transport to better diversify the production of vaccines and other life-saving medical devices.
Louis Pasteur once said,Science knows no country, because knowledge belongs to humanity, and it is the torch that will illuminate the world.“The wisdom of Pasteur’s vision is more appealing than ever before. In the interest of all humanity, we must now play our part in ensuring that the fruits of our knowledge are distributed quickly and equitably.”
** Originally 60 percent by mid-2022, but increased to 70 percent with increasing variance of the new variant.